1. Home
  2. CNC vs UTHR Comparison

CNC vs UTHR Comparison

Compare CNC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centene Corporation

CNC

Centene Corporation

HOLD

Current Price

$38.37

Market Cap

18.5B

Sector

Health Care

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNC
UTHR
Founded
1984
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.5B
20.3B
IPO Year
2001
1999

Fundamental Metrics

Financial Performance
Metric
CNC
UTHR
Price
$38.37
$488.92
Analyst Decision
Hold
Buy
Analyst Count
17
12
Target Price
$40.06
$495.08
AVG Volume (30 Days)
8.4M
424.3K
Earning Date
10-29-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.08
EPS
N/A
26.38
Revenue
$167,680,000,000.00
$3,128,400,000.00
Revenue This Year
$32.54
$13.64
Revenue Next Year
$0.19
$5.78
P/E Ratio
N/A
$18.55
Revenue Growth
14.57
13.50
52 Week Low
$25.08
$266.98
52 Week High
$66.81
$492.62

Technical Indicators

Market Signals
Indicator
CNC
UTHR
Relative Strength Index (RSI) 55.23 68.10
Support Level $37.41 $470.13
Resistance Level $39.34 $492.62
Average True Range (ATR) 1.38 10.72
MACD 0.07 -0.53
Stochastic Oscillator 70.49 89.55

Price Performance

Historical Comparison
CNC
UTHR

About CNC Centene Corporation

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: